Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

HIMS Stock's Valuation Looks Reasonable As stated above, HIMS stock's valuation looks reasonable now. Let's use a reverse DCF, as I did in my HIMS article from November, to figure out how much ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears "aspirational." ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Hims & Hers Health (HIMS) is jumping 15% after the company announced that it had made an acquisition which will allow it to launch at-home lab testing. Hims & Hers owns and operates an online ...

Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...